Bioxytran Amends Preferred Stock Conversion Rules and Grants Significant Equity Award to CEO

summarizeSummary

Bioxytran, Inc. has amended its Convertible Preferred Stock terms to require board and preferred shareholder approval for conversion, while also granting 6 million shares of Convertible Preferred Stock to its CEO as a performance award.

check_boxKey Events

• Preferred Stock Conversion Rules Amended

  The company filed an amendment to its Certificate of Designation of Convertible Preferred Stock, effective February 18, 2026. This amendment requires approval from both the Board of Directors and a majority of outstanding Preferred Stockholders for any conversion of Convertible Preferred Stock into Common Stock.

• CEO Receives Significant Equity Award

  CEO David Platt was granted 6,000,000 shares of the company's Convertible Preferred Stock as a performance-based award. This grant recognizes his role in securing a commercial distribution agreement and advancing capital funding initiatives.

auto_awesomeAnalysis

This 8-K filing details two significant events for Bioxytran. First, the company has implemented a new governance measure, effective February 18, 2026, requiring both board and majority preferred shareholder approval for any conversion of Convertible Preferred Stock into common stock. This change aims to provide greater control over potential dilution. Second, the company granted 6,000,000 shares of Convertible Preferred Stock to CEO David Platt as a performance-based award. This substantial equity grant, tied to commercialization and capital funding initiatives, represents a significant potential future dilution for common shareholders, estimated at over 6% of the current market capitalization if fully converted. This grant follows recent positive clinical trial results, indicating a focus on advancing the company's drug candidate, and the amendment to conversion rights could be seen as a balancing measure to manage the impact of such large grants.